Phenytoin and Elevated Liver Enzymes
Yes, phenytoin can cause elevated liver enzymes and hepatotoxicity, though this is rare (occurring in <1% of patients), and management depends on the severity and pattern of elevation. 1
Can Phenytoin Cause Elevated Liver Enzymes?
Phenytoin is hepatotoxic through multiple mechanisms:
Hypersensitivity hepatotoxicity: The most commonly reported pattern involves a multisystem hypersensitivity reaction occurring within the first 6 weeks of therapy, presenting with fever, rash, lymphadenopathy, and hepatomegaly alongside elevated transaminases, alkaline phosphatase, bilirubin, and prolonged prothrombin time 2, 3
Chronic enzyme elevation: Prolonged mild-to-moderate liver enzyme elevations can occur during long-term therapy and may progress to hepatic fibrosis, even without hypersensitivity features 4
Mixed hepatocellular injury: Pathologic findings show both cholestasis and necrosis 2
The FDA label explicitly warns that phenytoin can cause hepatotoxicity, particularly in patients with impaired liver function, elderly patients, or those who are gravely ill 1. Black patients may have an increased (though still rare) risk of hepatotoxicity 1.
Recommended Management Algorithm
Baseline Assessment
- Check liver function tests (ALT, AST, alkaline phosphatase, bilirubin) before initiating phenytoin
- Document baseline values, especially in patients with pre-existing liver disease 5
Monitoring During Therapy
Early phase (first 6 weeks):
- Monitor for hypersensitivity symptoms: fever, rash, lymphadenopathy, jaundice, right upper quadrant pain
- Check liver enzymes if any symptoms develop 1, 3
Ongoing therapy:
- Periodic monitoring of liver enzymes, particularly in high-risk patients (elderly, those with liver disease, concurrent hepatotoxic medications)
- More frequent monitoring if mild elevations detected 5
Management Based on Severity
Mild elevations (ALT/AST <3× ULN):
- Continue phenytoin with increased monitoring frequency (weekly to biweekly)
- Investigate alternative causes of elevation
- Consider checking free phenytoin levels, especially in elderly or critically ill patients with low albumin 6
Moderate elevations (ALT/AST 3-5× ULN):
- Hold phenytoin temporarily
- Monitor liver enzymes every 3 days
- Investigate alternative causes (viral hepatitis, other medications, alcohol)
- If enzymes normalize within 1-2 weeks, may cautiously resume with close monitoring 7
- If persistent beyond 2 weeks, consider permanent discontinuation
Severe elevations (ALT/AST >5× ULN or any elevation with bilirubin >2× ULN):
- Permanently discontinue phenytoin immediately 7
- This represents potential serious hepatotoxicity with significant morbidity and mortality risk 2, 3
Any elevation with hypersensitivity features (rash, fever, lymphadenopathy):
- Discontinue phenytoin immediately and permanently 1
- Do not rechallenge—this can be fatal 3
- Consider alternative anticonvulsants that are not structurally similar (avoid other hydantoins, barbiturates) 1
Alternative Anticonvulsants in Liver Disease
When phenytoin must be discontinued or avoided in patients with liver disease:
Preferred alternatives (minimal hepatic metabolism):
- Levetiracetam (first choice—available IV, no hepatic metabolism) 8, 9
- Lacosamide (available IV) 8
- Gabapentin 8
- Pregabalin 8
Avoid:
- Valproic acid (high hepatotoxicity risk) 8
- Felbamate (high hepatotoxicity risk) 8
- Phenobarbital (extensive hepatic metabolism) 8
Critical Pitfalls to Avoid
Don't rely solely on total phenytoin levels in patients with low albumin: Calculate free phenytoin using the Sheiner-Tozer equation or measure directly, as toxicity can occur with "normal" total levels 6
Don't continue phenytoin if rash develops: Even mild rashes warrant discontinuation, as progression to Stevens-Johnson syndrome or toxic epidermal necrolysis can be fatal 1
Don't rechallenge after hepatotoxicity: This can precipitate fatal reactions 3
Monitor drug interactions: Phenytoin induces hepatic enzymes and interacts with numerous medications; patients taking other hepatotoxic drugs (methotrexate, statins) require closer monitoring 10, 11, 12
Don't delay discontinuation in severe cases: Mortality has been reported with phenytoin hepatotoxicity; when ALT >5× ULN or accompanied by elevated bilirubin, immediate permanent discontinuation is warranted 7, 2